Integra LifeSciences Holdings Corporation
IARTNASDAQHealthcare● Active
$16.94
$-0.05(-0.29%)
Market Cap$1.3B
P/E Ratio—
52W High$17.42
52W Low$8.7
Integra LifeSciences Holdings Corporation (IART) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IART · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.54
Est. $0.41 · +31.7%
Revenue
$0.39B
Est. $0.38B · +2.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
IART reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $0.49 | — | — | — | $0.42B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $0.41 | $0.54 | +31.7% | $0.39B | $0.38B | +2.6% |
| ▲ Q1 FY2026 | Feb 26, 2026 | $0.79 | $0.83 | +5.1% | $0.43B | $0.43B | +1.2% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $0.43 | $0.54 | +25.6% | $0.40B | $0.43B | -6.4% |
| ▲ Q3 FY2025 | Jul 31, 2025 | $0.43 | $0.45 | +4.7% | $0.42B | $0.41B | +0.3% |
| ▼ Q2 FY2025 | May 5, 2025 | $0.43 | $0.41 | -4.7% | $0.38B | $0.40B | -5.0% |
| ▲ Q1 FY2025 | Feb 25, 2025 | $0.86 | $0.97 | +12.8% | $0.44B | $0.41B | +7.5% |
| ▲ Q4 FY2024 | Nov 4, 2024 | $0.39 | $0.41 | +5.1% | $0.38B | $0.45B | -14.5% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$0.49
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.54
EPS Est.
$0.41
EPS Surpr.
+31.7%
Revenue
$0.39B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$0.83
EPS Est.
$0.79
EPS Surpr.
+5.1%
Revenue
$0.43B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$0.54
EPS Est.
$0.43
EPS Surpr.
+25.6%
Revenue
$0.40B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$0.45
EPS Est.
$0.43
EPS Surpr.
+4.7%
Revenue
$0.42B
Q2 FY2025
May 5, 2025Miss
EPS Actual
$0.41
EPS Est.
$0.43
EPS Surpr.
-4.7%
Revenue
$0.38B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
$0.97
EPS Est.
$0.86
EPS Surpr.
+12.8%
Revenue
$0.44B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
$0.41
EPS Est.
$0.39
EPS Surpr.
+5.1%
Revenue
$0.38B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.86 | $0.87 | $0.88 | 3 |
| Q3 FY2028 | $0.74 | $0.76 | $0.76 | 3 |
| Q2 FY2028 | $0.71 | $0.72 | $0.73 | 3 |
| Q1 FY2028 | $0.61 | $0.61 | $0.62 | 3 |
| Q4 FY2027 | $0.79 | $0.80 | $0.81 | 2 |
| Q3 FY2027 | $0.67 | $0.68 | $0.69 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.5B | $0.5B | $0.5B | 2 |
| Q3 FY2028 | $0.5B | $0.5B | $0.5B | 2 |
| Q2 FY2028 | $0.4B | $0.5B | $0.5B | 2 |
| Q1 FY2028 | $0.4B | $0.4B | $0.4B | 2 |
| Q4 FY2027 | $0.5B | $0.5B | $0.5B | 3 |
| Q3 FY2027 | $0.4B | $0.4B | $0.4B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +31.7% | $10.65 | $13.22 | +24.13% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +5.1% | $11.59 | $11.33 | -2.24% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +25.6% | $15.43 | $11.81 | -23.46% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +4.7% | $12.37 | $13.14 | +6.22% |
| ▼ Q2 FY2025 | May 5, 2025 | -4.7% | $16.85 | $13.28 | -21.19% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +12.8% | $22.05 | $24.72 | +12.11% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +5.1% | $19.28 | $24.12 | +25.10% |
| ▲ Q3 FY2024 | Jul 29, 2024 | +1.6% | $31.43 | $25.42 | -19.12% |
Q2 FY2026+24.13%
Report Date
May 5, 2026
EPS Beat/Miss
+31.7%
Price Before
$10.65
Price After
$13.22
Q1 FY2026-2.24%
Report Date
Feb 26, 2026
EPS Beat/Miss
+5.1%
Price Before
$11.59
Price After
$11.33
Q4 FY2025-23.46%
Report Date
Oct 30, 2025
EPS Beat/Miss
+25.6%
Price Before
$15.43
Price After
$11.81
Q3 FY2025+6.22%
Report Date
Jul 31, 2025
EPS Beat/Miss
+4.7%
Price Before
$12.37
Price After
$13.14
Q2 FY2025-21.19%
Report Date
May 5, 2025
EPS Beat/Miss
-4.7%
Price Before
$16.85
Price After
$13.28
Q1 FY2025+12.11%
Report Date
Feb 25, 2025
EPS Beat/Miss
+12.8%
Price Before
$22.05
Price After
$24.72
Q4 FY2024+25.10%
Report Date
Nov 4, 2024
EPS Beat/Miss
+5.1%
Price Before
$19.28
Price After
$24.12
Q3 FY2024-19.12%
Report Date
Jul 29, 2024
EPS Beat/Miss
+1.6%
Price Before
$31.43
Price After
$25.42
Avg Beat Reaction+3.25%
Avg Miss Reaction-21.19%
Beat Rate7 / 8 quarters
Largest Move+25.10% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IART ends December
Integra LifeSciences Holdings Corporation (IART) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.54 — beating the analyst consensus of $0.41 by +31.7%. IART has beaten EPS estimates for 4 consecutive quarters. The next IART earnings date is expected around September 1, 2026.
Each quarter, investors track IART earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IART revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IART's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IART earnings · 5 questionsIntegra LifeSciences Holdings Corporation's next earnings report is expected around September 1, 2026. IART typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IART historically reports after market close (AMC).
IART earnings datewhen is IART earningsIART next earnings datewhen does IART report earningsIART earnings calendar
▸ Source: FMP · Integra LifeSciences Holdings Corporation SEC filings · US GAAP · Integra LifeSciences Holdings Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026